93.317: Emerging Infections Programs
Sept. 2, 2022
Sept. 2, 2022
The purpose of the Emerging Infections Programs (EIP) is to assist in local, state, and national efforts to prevent, control, and monitor the public health impact of infectious diseases. The EIP cooperative agreement was formed in 1995 as a key component of CDC’s national strategy to address and reduce emerging infectious disease (EID) threats. The EIP is a population-based network of state health agencies and their collaborators, including (but not limited to) academic institutions, local health departments, public health and clinical laboratories, infection control professionals, and healthcare providers. The network plays a critical role in conducting surveillance and applied epidemiologic and laboratory research, implementing and evaluating prevention and intervention projects, and responding quickly to new infectious disease issues. The unique strength of the EIP lies in the network’s ability to quickly translate surveillance and research activities into informed policy and public health practice.
Type of Assistance
B - Cooperative Agreements
Eligibility is limited to State governments (specifically, state health departments) or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau). The EIP infrastructure depends on a direct relationship with public health agencies that have sufficient legal authority and responsibility to perform public health surveillance and response activities. The network must also consist of definitive populations large enough to adequately determine disease burden, evaluate large scale interventions, and impact public health policy decisions.
Beneficiaries of this program include State and local health departments, the District of Columbia, U.S. Territories, and the general public.